EU Approves Sanofi/Regeneron's Cholesterol-Buster Praluent

Monday, September 28, 2015

Source: PharmaTimes

European regulators have approved Sanofi/Regeneron’s Praluent to reign in ‘bad’ cholesterol levels in certain patients for whom statins aren’t working or can’t be tolerated.

Specifically, the drug has been green-lighted for treatment of primary hypercholesterolaemia or mixed dyslipidaemia as an adjunct to diet, either alongside a statin-based regimen or alone or in combination with other lipid-lowering therapies when statins cannot be taken.

 

View All News »